Skip to main content
main-content

07-12-2018 | Breast cancer | Video

Circulating tumour cell count could aid first-line hormone versus chemotherapy treatment decisions

Francois-Clement Bidard reports findings that circulating tumour cell count could help oncologists choose between first line hormone therapy and chemotherapy in women with oestrogen receptor positive, HER2-negative metastatic breast cancer (3:23).

Funding for this video was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.

image credits